RxDoctor Payments DataLook up a doctor →

Mark Clark

Acute Care · Gainesville, GANPI 1285631887

Payments from drug & device makers

$10,380in general payments, 2019–2025

Across 402 payments — averaging $25.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$1K
  • Exelixis Inc.$867
  • Johnson & Johnson$609
  • Seagen Inc.$485
  • AbbVie$475
  • AstraZeneca$461
  • plus $6K from 48 others

What the payments were for

  • Consulting fees$9329%
  • Food & beverage$9,23589%
  • Education$2132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,380 in reported general payments places this provider in the 95th percentile of 679 acute care providers in Georgia.

See all acute care providers in Georgia

Medicare billing

Part B allowed, 2024
$48,230
Medicare patients
249
Services billed
611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide73$981,761
QinlockRipretinib12$494,955
NubeqaDarolutamide23$302,921
TagrissoOsimertinib Mesylate15$246,189
PromactaEltrombopag Olamine12$223,088
CalquenceAcalabrutinib Maleate13$196,161
GilotrifAfatinib Dimaleate13$154,483
EliquisApixaban134$89,654
XareltoRivaroxaban68$59,351
CreonLipase/Protease/Amylase15$46,630
ZenpepLipase/Protease/Amylase11$39,567
Imatinib Mesylate20$23,477
Exemestane14$5,023
Enoxaparin Sodium22$4,454
Ondansetron Hcl91$3,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$147$981,76173 claims
Deciphera Pharmaceuticals Inc.Qinlock$188$494,95512 claims
AstraZenecaTagrisso, Calquence$461$442,34928 claims
BayerNubeqa$303$302,92123 claims
NovartisPromacta$82$223,08812 claims
PfizerEliquis$365$89,654134 claims
Johnson & JohnsonXarelto$609$59,35168 claims
AbbVieCreon, Synthroid$475$47,36827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 acute care providers in Georgia.

Other acute care in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →